Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Luminous ROI

Why Lumena opted for an acquisition over an IPO

Luminous ROI

Although Lumena Pharmaceuticals Inc. tested the IPO waters, its investors decided to take the bird in hand offered by Shire plc (LSE:SHP; NASDAQ:SHPG) and by doing so will get at least a 3.5x return based on the upfront payment

Read the full 409 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE